Metastatic melanoma: Chemotherapy

Emilio Bajetta, Michele Del Vecchio, Chantal Bernard-Marty, Milena Vitali, Roberto Buzzoni, Olivier Rixe, Paola Nova, Stefania Aglione, Sophie Taillibert, David Khayat

Research output: Contribution to journalArticle

Abstract

The incidence of cutaneous melanoma has been rapidly increasing, with an estimate of 47,700 new cases diagnosed in 2000 in the United States. In the early phase of its natural history, melanoma is cured in most cases by surgery, but once the metastatic phase develops, it is almost always fatal. The treatment of metastatic melanoma remains unsatisfactory. Systemic therapy has not been successful up to now, with very low response rates to single-agent chemotherapy. Polychemotherapy has increased the response rate (RR), without a significant improvement in overall survival. Immunotherapy alone is able to induce only a few durable complete responses (CRs). New chemotherapeutic and biologic agents are now available and promising combined approaches targeting the tumor by several different mechanisms are desirable and will probably represent the future modality of treatment.

Original languageEnglish
Pages (from-to)427-445
Number of pages19
JournalSeminars in Oncology
Volume29
Issue number5
DOIs
Publication statusPublished - Oct 2 2002

    Fingerprint

ASJC Scopus subject areas

  • Oncology

Cite this

Bajetta, E., Del Vecchio, M., Bernard-Marty, C., Vitali, M., Buzzoni, R., Rixe, O., Nova, P., Aglione, S., Taillibert, S., & Khayat, D. (2002). Metastatic melanoma: Chemotherapy. Seminars in Oncology, 29(5), 427-445. https://doi.org/10.1053/sonc.2002.35238